Is Non-Hodgkin Lymphoma the only cancer in the Roundup lawsuit?

Functionally yes, as of 2026. Non-Hodgkin Lymphoma and its B-cell and T-cell subtypes are the basis for the overwhelming majority of MDL 2741 claims. Other cancers (leukemia, multiple myeloma, kidney cancer, bladder cancer, brain cancer) have been raised in discussions and in early filings but are not the basis for active claims in the MDL today. This is general information about the litigation, not legal advice. Talk to a licensed mass tort attorney in your state about your specific diagnosis and facts.

Can I file a Roundup claim if I had residential exposure only?

Yes. MDL 2741 has accepted residential homeowner claims. Commercial and agricultural exposure typically produces a stronger evidentiary profile because the cumulative dose is higher, but residential use is not a categorical bar. Document your purchase history, application frequency, and years of use as completely as you can.

What if my family member died from Non-Hodgkin Lymphoma after Roundup exposure?

You may have a wrongful-death claim. Wrongful-death claims have separate statutes of limitations from regular personal injury claims, often running from the date of death rather than the date of diagnosis. These windows are shorter in most states. If you are considering a wrongful-death claim, contact a licensed attorney in your state promptly. This is not legal advice. The specific deadlines and procedural rules vary by state.

Has Bayer settled the Roundup lawsuits?

Bayer has reached settlements covering a significant portion of historical claims, with reported aggregate settlement figures in the multi-billion-dollar range since 2020. Bayer continues to fight individual cases, and new claims are still being accepted in MDL 2741 and in state-court actions in some jurisdictions. The settlement framework has shifted multiple times and current settlement specifics for any individual case depend on facts a licensed mass tort attorney would review on intake.

Is there a deadline to file a Roundup claim?

Yes, and it varies by state. Most states have a 2 to 3 year statute of limitations for personal injury claims, but the clock typically starts on discovery (when you knew or reasonably should have known of the connection between Roundup exposure and your NHL diagnosis) rather than on the date of exposure. Some states (Missouri, for example) have longer windows. Wrongful-death claims have separate, often shorter, deadlines. This is not legal advice. Filing windows vary by state and by the specific facts of your case. Talk to a licensed attorney in your state to confirm your specific deadline.

How much can I expect to receive from a Roundup settlement?

No one can promise a specific settlement amount for any individual case. Past reported settlements in Roundup litigation have spanned from low five figures to seven figures depending on the strength of the exposure profile, the NHL subtype and severity, the cumulative medical and economic damages, and the jurisdiction. Anyone telling you up front what your specific case is worth is overstating what they know. This is general information about reported settlement ranges, not a prediction of your specific outcome. Talk to a licensed mass tort attorney about your specific facts.

Do I need a lawyer who specializes in Roundup specifically?

You want a lawyer or firm that has actively filed cases in MDL 2741 specifically. The mass tort plaintiffs' bar is large and many firms advertise mass tort representation, but the firms that have actually litigated Roundup cases through MDL discovery, deposition, and trial have a meaningful advantage in case valuation and settlement negotiation. When interviewing firms, ask specifically: how many Roundup cases the firm has filed in MDL 2741, how many have settled, and whether the firm has been part of any of the bellwether trials.

What Cancers Are Included in the Roundup Lawsuit? (2026 MDL Update)

The Roundup lawsuit is functionally a Non-Hodgkin Lymphoma lawsuit. Non-Hodgkin Lymphoma (NHL) is the cancer with the strongest scientific evidence linking long-term Roundup (glyphosate) exposure to disease, the cancer that won the Hardeman, Pilliod, and Johnson cases in California, and the cancer at the center of MDL 2741 in the Northern District of California, Judge Vince Chhabria presiding.

NHL is an umbrella term that covers a number of cancer subtypes, several of which have specifically been the basis for successful Roundup claims. Other cancers are sometimes asked about (leukemia, multiple myeloma, kidney cancer), but their scientific connection to glyphosate is weaker and they have not been the basis for the bulk of MDL 2741 filings.

This article walks the specific NHL subtypes that qualify, the exposure documentation that matters, the cancers that are not in the MDL, and the current procedural status as of 2026.

Last updated: 2026. Current MDL status: MDL 2741 (In re: Roundup Products Liability Litigation), Northern District of California, Judge Vince Chhabria. Bayer (Monsanto) has reached settlements with a significant portion of historical claimants while continuing to fight new individual cases.

Non-Hodgkin Lymphoma (NHL): the primary cancer in MDL 2741

Non-Hodgkin Lymphoma is the cancer at the center of Roundup litigation. It is a cancer of the lymphatic system, the network of lymph nodes and vessels that runs throughout the body and is part of the immune system. NHL is not one disease but a group of related blood cancers that share a common origin in lymphocytes.

The link between Roundup (the herbicide containing glyphosate) and NHL is based on:

·The IARC 2015 classification. The International Agency for Research on Cancer classified glyphosate as Group 2A (probably carcinogenic to humans), citing evidence specifically for NHL.
·Epidemiological studies (including the Agricultural Health Study and meta-analyses by Zhang et al. 2019) showing increased NHL risk with high-cumulative-exposure glyphosate use.
·Internal Monsanto documents disclosed in litigation showing the company's own awareness of the NHL signal in the scientific literature going back decades.
·Successful trial verdicts in Hardeman v. Monsanto, Johnson v. Monsanto, and Pilliod v. Monsanto, where juries found in favor of NHL plaintiffs against Monsanto.

If you have been diagnosed with Non-Hodgkin Lymphoma and have a documented history of Roundup exposure (residential, commercial, or agricultural), you have the core elements of a Roundup claim. The specific subtype of NHL matters less than the diagnosis itself for purposes of qualification, though some subtypes have more case history than others.

NHL subtypes that qualify

The following NHL subtypes have been the basis for Roundup claims in MDL 2741:

·Diffuse Large B-Cell Lymphoma (DLBCL). The most common NHL subtype overall (about one-third of all NHL cases) and one of the most-frequently litigated Roundup subtypes.
·Follicular Lymphoma. The second most common subtype, generally slow-growing.
·Mantle Cell Lymphoma. A more aggressive subtype with a distinctive genetic signature.
·Marginal Zone Lymphoma. Includes the splenic, nodal, and extranodal (MALT) variants.
·Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia. A rarer indolent subtype.
·Burkitt Lymphoma. An aggressive B-cell NHL, less common in adults.
·Small Lymphocytic Lymphoma (SLL). The tissue-based form of CLL (chronic lymphocytic leukemia); see leukemia section below for the blood-based form.
·T-cell lymphomas (peripheral T-cell, anaplastic large cell, cutaneous T-cell). T-cell NHLs are less common but documented in claims.
·Hairy Cell Leukemia. Despite the name, hairy cell leukemia is classified as a B-cell NHL by the WHO classification system and has been the basis for Roundup claims.

If your diagnosis is NHL but the specific subtype is not on this list, talk to a licensed attorney in your state. The MDL has not formally excluded any NHL subtype, and the specific subtype is part of the medical and exposure analysis a lawyer would perform on intake.

Cancers that are NOT in MDL 2741

Claimants frequently ask about cancers that are not part of the Roundup MDL. Being clear: as of the current state of MDL 2741, these cancers are not the basis for active Roundup claims:

·Leukemia (most types). Acute leukemias (AML, ALL) and chronic leukemias (CLL, CML) are blood cancers but are not currently in MDL 2741. Note the exception above for Small Lymphocytic Lymphoma, which is the tissue-based form of CLL and is classified as NHL.
·Multiple Myeloma. A cancer of plasma cells. Some epidemiological studies have suggested a possible association with herbicide exposure, but multiple myeloma is not the basis for the bulk of MDL 2741 filings and the scientific evidence is weaker than for NHL.
·Kidney cancer. Renal cell carcinoma and other kidney cancers are not in MDL 2741.
·Liver cancer. Not in MDL 2741.
·Bladder cancer. Not in MDL 2741.
·Brain cancer (gliomas). Not in MDL 2741.
·Colorectal cancer. Not in MDL 2741.
·Lung cancer. Not in MDL 2741.
·Prostate cancer. Not in MDL 2741.
·Breast cancer. Not in MDL 2741.

If you have one of these cancers and a history of Roundup exposure, you are not automatically excluded from a future claim if the science evolves, but you do not have a current Roundup claim. A licensed mass tort attorney can review your specific facts.

What counts as Roundup exposure

Three categories of exposure show up in MDL 2741 claims:

Residential use. Long-term homeowner use of Roundup in the yard or garden. The MDL has accepted residential claims, though commercial and agricultural use carries higher cumulative-exposure totals and tends to be the stronger evidentiary profile. Document your purchase history (receipts, garden-center loyalty programs, credit card records), your application frequency, the years of use, and the application method (sprayer, wand, ready-to-use bottles).

Commercial / occupational use. Landscapers, golf course workers, nursery employees, parks and recreation staff, pest control technicians, school grounds workers. Commercial use is typically the strongest exposure profile because it involves frequent, high-volume application over years.

Agricultural use. Farmers and farm workers who applied Roundup or who worked on Roundup-treated land. The Agricultural Health Study (still ongoing) is one of the primary epidemiological data sources for agricultural exposure.

The stronger your exposure documentation, the stronger the claim. Most lawyers will help you build the exposure history during intake if you have the broad strokes (years used, type of use, geographic area). The diagnosis is the necessary condition; the exposure history is what makes the case actionable.

Statute of limitations: state-by-state

Roundup lawsuit filing windows depend on your state and on when you knew (or reasonably should have known) of the connection between your exposure and your NHL diagnosis. This is the discovery rule and it applies in most states.

General civil tort statutes of limitations that commonly apply to Roundup claims:

·California: 2 years from discovery (CCP 335.1).
·Texas: 2 years from discovery (Tex. Civ. Prac. & Rem. Code 16.003).
·Florida: 2 years from discovery (Fla. Stat. 95.11, post-2023 tort reform; pre-2023 claims may have a longer window).
·New York: 3 years from discovery (CPLR 214).
·Pennsylvania: 2 years from discovery (42 Pa.C.S. 5524).
·Illinois: 2 years from discovery (735 ILCS 5/13-202).
·Missouri: 5 years (Mo. Rev. Stat. 516.120) - notably longer.

The filing window varies by state, and the discovery-rule trigger date depends on your specific facts. Wrongful-death claims (where the NHL claimant has died) have separate, often shorter, statutes that run from date of death rather than date of diagnosis or discovery. This is not legal advice. Talk to a licensed attorney in your state to confirm the specific deadline that applies to your case.

Current settlement framework

Bayer has reached settlements covering a significant portion of historical Roundup claims since 2020, with reported aggregate settlement figures in the multi-billion-dollar range across MDL 2741 and related state-court actions. The settlement framework has shifted multiple times. As of 2026:

·Bayer continues to fight individual cases, with mixed verdicts in MDL 2741 bellwether trials and in state-court matters.
·New individual claimants are still being accepted in MDL 2741 and in state courts in some jurisdictions.
·Settlement amounts vary based on the strength of the exposure profile, the NHL subtype and severity, the cumulative medical and economic damages, and the jurisdiction.

No one can promise a specific settlement amount for any individual case. Past reported settlements in this litigation have ranged from low five figures to seven figures depending on the factors above. Anyone telling you up front what your specific case is worth is overstating what they know. The honest answer is a range, qualified by the strength of the exposure and medical documentation, and dependent on case-specific facts a lawyer would review on intake.

What to do if you think you have a claim

If you have been diagnosed with Non-Hodgkin Lymphoma (or one of the NHL subtypes listed above) and have a documented history of Roundup exposure:

Do not delay because of the statute of limitations. The filing windows are narrower than people expect. Even if you think you might still have years, get a free consultation now.
Gather your medical records related to the NHL diagnosis. The pathology report (especially the specific subtype classification), the treatment history, and any documentation of when the diagnosis was made.
Document your exposure history. Years of Roundup use, application method, frequency, geographic area, type of use (residential / commercial / agricultural).
Get a claim review from a licensed attorney who has experience with MDL 2741 specifically. The mass tort plaintiffs' bar is large but specialized; you want a firm that has actually filed cases in this MDL.

Claim reviews are free in mass tort cases. The attorney works on contingency and only collects a fee if the claim succeeds.